<DOC>
	<DOCNO>NCT02164253</DOCNO>
	<brief_summary>The FAIR-ALS study investigate safety efficacy scavenger treatment iron deferiprone , would reduce brain iron limit development amyotrophic lateral sclerosis . It show excess iron central nervous system carry sporadic ALS patient . Iron overload associate loss motor neuron may explain sign disease ( atrophy ) . The investigator discuss hypothesis reduce excess iron , investigator reduce loss neuron thus progression sign disease .</brief_summary>
	<brief_title>Focal Accumulation Iron Cerebral Regions Early ALS ( Amyotrophic Lateral Sclerosis ) Patients</brief_title>
	<detailed_description>At end study , propose continue usual quarterly patient follow , recommend French ALS center . Deferiprone administer part compassionate use , patient want hypoxemia . We therefore plan treatment period compassionate relatively short less 3 year .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>Amyotrophic lateral sclerosis define accordance El Escorial criterion ( possible , probable define ) 18 85 year old patient , male female Patient social security cover Achieved respiratory define FVC &lt; 70 % Evolution 24 month Demented subject Severe malnutrition Patients treatment potentially risk agranulocytosis neutropenia Patients history agranulocytosis iatrogenic haematological disease Incapable give consent Indication MRI Indication lumbar puncture Patient refuse lumbar puncture Hypersensitivity iron chelators Concomitant treatment antacid contain aluminum Presence another serious illness lifethreatening disable con use treatment mixture oxygen nitrous oxide equally</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>